<DOC>
	<DOCNO>NCT02838628</DOCNO>
	<brief_summary>In study , activity , safety , pharmacokinetics ( PK ) KX2-391 Ointment evaluate adult subject clinical diagnosis stable , clinically typical actinic keratosis ( AK ) face scalp .</brief_summary>
	<brief_title>A Ph2a , Open-Label , Multicenter , Activity &amp; Safety Study KX2-391 Oint Subj . w Actinic Keratosis Face Scalp</brief_title>
	<detailed_description>This study open-label , multicenter , activity , safety , tolerability , PK study KX2-391 Ointment administer topically face scalp subject actinic keratosis . The study consist Screening , Treatment , Follow-up Periods . Eligible subject receive X consecutive day topical treatment , apply study site . Blood sample PK analysis collect . Activity ( lesion count ) safety evaluation perform .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<criteria>1 . Males females â‰¥18 year old 2 . Clinical diagnosis stable , clinically typical actinic keratosis 3 . A define treatment area face scalp 4 . Females must postmenopausal , surgically sterile otherwise incapable pregnancy least 1 year ; must use highly effective contraception least 90 day prior treatment KX2391 Ointment 5 . Males vasectomy must agree use barrier contraception 6 . Subjects judgment Investigator , good general health 7 . Willing avoid excessive sun exposure 8 . Able comprehend willing sign inform consent form ( ICF ) 1 . Clinically atypical and/or rapidly change AK lesion treatment area 2 . Malignancy within 5 year prior Screening except basal squamous cell carcinoma treatment area treat curative intent without recurrence 3 . Used retinoids , glucocorticosteroids methotrexate antimetabolite within , 90 day , Visit 1 4 . Used topical therapy , treatment , surgical destructive modality treatment area within , 90 day , Visit 1 5 . Currently , experience cutaneous malignancy , sunburn body art treatment area within , 180 day , Visit 1 6 . A history sensitivity and/or allergy ingredient study medication 7 . A skin disease condition , opinion Investigator , might interfere study conduct evaluation , expose subject unacceptable risk study participation 8 . Other significant uncontrolled unstable medical disease condition , opinion Investigator , would expose subject unacceptable risk study participation 9 . Females pregnant nursing 10 . Participated investigational drug trial investigational study medication administer within 14 day 5 halflives investigational product , whichever longer , Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>